INTERVACC Aktie

 

Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 14 May 2025, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted the Board of Directors' submitted income statement and balance sheet for the parent company and the group for the financial year 2024. Appropriation of the company's profit or loss The AGM resolved, in accordance with the Board of Directors' proposal, that no dividend shall be paid for the financial year 2024, and that the result shall be balanced in a new account. Discharge...

Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), will launch Strangvac in Finland and vaccine vials are expected to be available for delivery shortly. This launch is the result of an extended collaboration between Intervacc and Dechra, where Dechra now has the right to sell Strangvac in Finland. This is a natural development given Dechra's long-standing presence and strong organization in Finland. “Dechra has a long and successful history in Finland, and it was a natural step for us to give Dechra the opportunity to sell Strangvac...

The scientific journal Vaccine has published an article entitled "Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection" (DOI: 10.1016/j.vaccine.2025.127077 (https://www.sciencedirect.com/science/article/pii/S0264410X25003743)), authored by a research team affiliated with Intervacc AB. The article describes the "proof-of-concept" study, which Intervacc previously reported positive results from, involving the vaccination of pregnant sows with a prototype vaccine against the bacterium Streptococcus suis to protect piglets from disease....

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 14 May 2025 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to Chapter 7, Section 4 a of the Swedish Companies Act and the Company's Articles of Associations. Therefore, shareholders may choose to exercise their voting rights at the AGM by attending by postal...

Intervacc AB (publ) announces that the company's 2024 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website intervacc.com (https://intervacc.se/en/investors/reports/). For more information please contact:   Jonas Sohlman, CEO Phone: +46 (0)8 120 10 600 E-mail: jonas.sohlman@intervacc.se   The information was submitted for publication, through the agency of the contact person set out above on April 4, 2025 at 08.30 CET. About Intervacc...

Intervacc AB (publ) today announces that the variation application previously submitted to the U.K's Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. As previously announced, the EMA has approved the corresponding variation application, and together these two approvals mark an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. "That we have now...

Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the recently completed rights issue. The members of the Nomination Committee have been appointed in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022. After the changes, the Nomination Committee in Intervacc before the Annual General Meeting 2025 has the following composition: · Staffan Lindstrand appointed by Healthcap. · Magnus Lundberg, appointed by...

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, RELEASE OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE REFER TO OMPIRTANT INFORMATION AT THE END OF THE PRESS RELEASE. Stockholm, 24 February 2025 The subscription period for the rights issue in Intervacc...

Das Instrument 2E9 SE0009607252 INTERVACC AB EQUITY wird cum Kapitalmassnahme gehandelt am 03.02.2025 und ex Kapitalmassnahme am 04.02.2025 The instrument 2E9 SE0009607252 INTERVACC AB EQUITY is traded cum capital adjustment on 03.02.2025 and ex capital adjustment on 04.02.2025...

Intervacc AB (publ) held an Extraordinary General Meeting (”EGM”) on Friday 31 January 2025, whereby it was resolved to approve the Board of Directors' proposal to amend the Articles of Association and to approve the Board of Directors' resolution on a rights issue. Today, the EGM resolved to approve the Board of Directors' resolution of 19 December 2024 to, through a new share issue with preferential rights for existing shareholders, increase the company's share capital by a maximum of SEK 53,015,384.80 through a new share issue of a maximum of 265,076,924 shares. Each shareholder has...

Stockholm, January 16, 2025 - Intervacc AB (publ) has received orders from Dechra Pharmaceuticals with a total order value equivalent to approximately SEK 5.8 million. Orders received relate to Strangvac, a vaccine against the highly contagious and serious infectious disease strangles that affects horses. The order value relates to vaccine vials for the regions of the UK, Germany, France, the Netherlands, Belgium and Austria and is expected to be delivered within the next 3–4 months. For more information please contact:   Jonas Sohlman, CEO Phone: +46 (0)8 120 10 600 E-mail:...

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Extraordinary General Meeting (“EGM”) to be held on Friday 31 January 2025 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has resolved that shareholders shall have the right, before the EGM, to exercise their voting rights in advance through postal voting pursuant to Chapter 7, Section 4 a of the Swedish Companies Act and the Company's Articles of Associations. Therefore, shareholders may choose to exercise their voting rights at the EGM by...

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, RELEASE OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE REFER TO OMPIRTANT INFORMATION AT THE END OF THE PRESS RELEASE. Stockholm 19 December 2024 The Board of Directors of Intervacc AB (publ) (“Intervacc”...

Stockholm, December 6, 2024 – Intervacc AB (publ) announces that Strangvac, a vaccine against equine strangles, is now back in stock for delivery in all European markets where the vaccine has been launched. The company applied for Special Batch Release (SBR), to allow for the recently manufactured batches to be available for sale. Today, the company can announce that after receiving approval for SBR in all local markets, Strangvac is available for immediate delivery in all markets where the product has been launched. The procedure and processes, including the Special Batch Release,...

Stockholm, November 11, 2024 – Intervacc AB (publ) will publish its interim report for the period January to September 2024 on Thursday 14 November 2024, at 08:30 CET. CEO Jonas Sohlman and CFO Jan Persson will present the report at a conference call and audiocast held on the same day at 11:00 CET. If you wish to participate via the audiocast, please go to the link below. https://intervacc.videosync.fi/intervacc-q3-report-2024 If you prefer to participate via conference call, please register using the link below. After registration, you will receive a phone number and a conference...

Stockholm, October 21, 2024 – Intervacc AB (publ) announces that the shortage situation for the equine strangles vaccine Strangvac in Sweden has been resolved and the vaccine is again in stock for distribution and sales. As previously announced, the shortage situation arose on October 1, 2024, and was expected to last until mid-October. The company applied through a special procedure, Special Batch Release (SBR), to allow for the newly manufactured batches available for sale. The company can today announce that after receiving approval for SBR in Sweden, Strangvac is available for...

Stockholm, September 20, 2024 - Intervacc AB (publ) predicts that the vaccine Strangvac, which is approved for sale in Europe and the UK, may be out-of-stock for a short period from the 1st October 2024. The doses of vaccine that are currently available for sale have a shelf-life that expires on the 30th September 2024 and Intervacc expects the out-of-stock situation in Sweden to be resolved during the first half of October. The out-of-stock situation is caused by the implementation of improved analytical methods that are used during the manufacturing process which, following their...

Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing patent protection from May 2031 to May 2036 on the UK market. The previously approved European patent for Strangvac is valid until May 2031. With the newly granted supplementary protection in the United Kingdom, along with previous applications in other European markets including Sweden, Benelux, Italy, Ireland, France, Spain,...

Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension means that the research group at the Karolinska Institutet, led by Professor Birgitta Henriques Normark, continues to be part of the successful collaboration between the KI, the Swedish University of Agricultural Sciences (SLU) and Intervacc. This collaboration has led to the development of Strangvac, a vaccine against the streptococcal infection...

Stockholm, July 31, 2024 - Intervacc AB (publ) announces that the reduction of share capital and nominal value, decided by the Annual General Meeting on May 15, 2024, has been registered by the Swedish Companies Registration Office. After registration, the nominal value is 0.20 SEK per share and the share capital amounts to 15,147,252.80 SEK after the reduction. The number of shares remains unchanged at 75,736,264. For more information please contact:   Jonas Sohlman, CEO E-mail: jonas.sohlman@intervacc.se Phone: +46 (0)8 120 10 600 The information was submitted for publication,...